Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. - Wikidata - awgldk - TriplyDB

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.

http://www.wikidata.org/entity/Q36545896

about

Management of pancreatic cancer in the elderly Management of borderline resectable pancreatic cancer Surgery for oligometastasis of pancreatic cancer Neoadjuvant therapy for localized pancreatic cancer: guiding principles Imaging preoperatively for pancreatic adenocarcinoma Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles Selection criteria in resectable pancreatic cancer: a biological and morphological approach SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.New challenges in perioperative management of pancreatic cancer Advances in chemotherapy for pancreatic cancer Systematic review of outcomes after distal pancreatectomy with coeliac axis resection for locally advanced pancreatic cancer.A 6-day clinical pathway after a pancreaticoduodenectomy is feasible, safe and efficient.Pancreas-protocol imaging at a high-volume center leads to improved preoperative staging of pancreatic ductal adenocarcinoma.Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer.Outcomes and prognostic factors of patients with stage IB and IIA pancreatic cancer according to the 8th edition American Joint Committee on Cancer criteria.Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer.Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.Escalating computed tomography angiogram (CTA) grade predicts unresectability and margin status for pancreaticobiliary neoplasms Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration Neoadjuvant strategies for pancreatic cancer Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer.Borderline resectable pancreatic cancer: definitions and management.Current and emerging therapies for the treatment of pancreatic cancer.Pancreatic adenocarcinoma Validation of group B borderline resectable pancreatic cancer: retrospective analysis.Maximum standardized uptake value on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas.Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy.Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival.Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expr Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells.

P2860

Q26774639-A71A4883-B424-474D-96AF-DC9BABA3A832 Q26781445-812F85CF-50B1-4D79-B921-67CC9ADECF3C Q26781546-32E0E6F4-6562-4A71-8E97-983401D385D0 Q26799428-EF626B50-C8EA-4511-9F11-01DCCBE4B302 Q26799450-DC7F82A5-B343-4B95-BFD5-AE8F52BD8111 Q26828959-C3C3FBB6-A6CC-46B0-8FA0-993CE086192E Q26859742-5D284183-E35D-4A2C-AEEB-66432B8DF3DB Q27851475-89BEEEF8-364E-4BE3-939E-4F621C6BB464 Q28082422-DE946E86-0E79-41EA-A0A7-944A2B35C527 Q28085711-04AECA2F-A8A0-4A24-9241-E56D07912E81 Q30249609-A6062930-BE43-4F63-82FD-C22CBD1C3204 Q30410995-0E139CF1-A589-4409-939D-2220F5EAECAF Q30430414-4BDF421B-020E-482F-8636-ABA6BB94852C Q30452636-1B2127DB-3795-4B81-BE3F-3DA4C52832C5 Q30540051-22F2436E-54E1-465A-B78A-CD21698F3ECB Q33408075-4603D83C-FCDC-4E02-A18F-537EBE4548E1 Q33558951-1D9081E7-E451-407E-8A0E-6395D96620A9 Q33590511-14F5D8E1-66D5-4519-965D-E6446A0A6397 Q33599558-9E4DAECC-5FB5-4E44-AC03-FB5980C5B603 Q33622827-BB0EFC0F-EA8E-4ED3-A6E4-6889149C5E92 Q33655712-E5247295-A1F4-4292-A044-62E760416D38 Q33665450-BACF4990-92D9-49EF-8EC8-73BE0B8F544B Q33679661-889C7883-E40A-4AA0-AAFC-A8DEED49350B Q33750803-C0C8024D-4072-4E8F-89BF-288142B75F22 Q33751263-763F127A-5EE6-4027-82AA-6D87FF5483EC Q33799457-AFF7716F-2221-48EB-90E5-CEBE7C1E365F Q33809495-039A6F73-F86C-4213-A54A-6656BCEC7790 Q33860986-CD891119-5073-4B77-8A80-9B6AC02E4E42 Q33948343-DD0161B6-E406-4759-A7AC-176F9B6DFAE4 Q34008107-07350026-AC61-4B4A-9341-5B7A011D909B Q34067852-D796E775-FF02-4781-8827-4AF9DE959CC5 Q34129346-071D7B5B-4F70-4F70-941B-C28B9E742E7B Q34140498-87D39428-7F30-49A7-9F5D-1A239631279F Q34182126-389E8187-DC26-40B0-83CD-2E510E3E6EE7 Q34243313-ADC2892D-0741-4672-A007-60CF4EDB2740 Q34277142-3B045BB5-DC62-4066-ABAA-881C4790CB5B Q34310131-507F46A1-63C0-48B1-8D0E-595679F34EB2 Q34408283-A993AA44-CB92-48C5-BB45-829D0DE9998A Q34493969-7FBED65E-5FD4-43EF-B3F4-D798B97F09ED Q34540060-970014D0-D56F-4630-988A-EDF100E7768E

P2860

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.

http://www.wikidata.org/entity/Q36545896

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Borderline resectable pancreat ...... role of preoperative therapy.

@ast

Borderline resectable pancreat ...... role of preoperative therapy.

@en

type

label

Borderline resectable pancreat ...... role of preoperative therapy.

@ast

Borderline resectable pancreat ...... role of preoperative therapy.

@en

prefLabel

Borderline resectable pancreat ...... role of preoperative therapy.

@ast

Borderline resectable pancreat ...... role of preoperative therapy.

@en

P1433

Q36545896-1FA20373-39C8-4D77-B8A3-6BFE033E782E

P1476

Q36545896-CED732ED-321E-45E1-A2DE-CEE313389ABB

P2093

Q36545896-0FDD2EA4-29D7-4728-B4B4-44270E31C9A2

Q36545896-320822C3-F677-417D-97F7-70756485DB4F

Q36545896-65ED4319-C94B-4E9B-AE09-CF967A41E379

Q36545896-664E335F-3B19-4FFE-B7CD-BD434EEC5AD0

Q36545896-935A9FBA-5028-410D-B4F7-658AC281DAFC

Q36545896-BE6D68BD-4DD2-40F3-973B-540DA9234C91

Q36545896-C0BE83D4-ADFE-4A5B-907B-0CC9F6E7D82A

Q36545896-CB159016-2342-4B24-A857-5633E0B85487

Q36545896-D2AFD91D-4254-4C90-9242-D78665144411

Q36545896-ED78DA30-4EA4-44A0-9848-5B9FBB9BF1D3

P2860

Q36545896-2FFB139C-7F27-4B40-9D7E-2B256D7C17ED

P2888

Q36545896-B4D0B64E-5B18-42F8-9403-4A1EB074AFEF

P304

Q36545896-8BEE0954-C09F-4AC9-B234-A6D4C107E12F

P31

Q36545896-83E9985C-D32B-4665-8EA0-4909B8F5F395

P356

Q36545896-E88ED6B1-80E6-4B53-AEF1-738B393DA284

P433

Q36545896-FCCD175C-234A-436A-A740-7CB688501C94

P478

Q36545896-2770B660-580F-4A2F-A35D-B27AEAB861AA

P577

Q36545896-CBAB4CBC-E4F4-4BFD-963A-A83B589FECC8

P6179

Q36545896-4BA32F13-F37D-4352-8948-370C0724E799

P698

Q36545896-347E78AE-413C-4D48-B4AC-6FFDC9D8FD70

P356

ASO.2006.08.011

P1433

Annals of Surgical Oncology

P1476

Borderline resectable pancreat ...... role of preoperative therapy.

@en

P2093

Christopher H Crane

http://www.w3.org/2001/XMLSchema#string

Douglas B Evans

http://www.w3.org/2001/XMLSchema#string

Eric P Tamm

http://www.w3.org/2001/XMLSchema#string

Gauri R Varadhachary

http://www.w3.org/2001/XMLSchema#string

Henry Q Xiong

http://www.w3.org/2001/XMLSchema#string

Huamin Wang

http://www.w3.org/2001/XMLSchema#string

James L Abbruzzese

http://www.w3.org/2001/XMLSchema#string

Jeffrey E Lee

http://www.w3.org/2001/XMLSchema#string

Peter W T Pisters

http://www.w3.org/2001/XMLSchema#string

Robert A Wolff

http://www.w3.org/2001/XMLSchema#string

P2860

Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT.

P2888

aso.2006.08.011

P304

1035-1046

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/ASO.2006.08.011

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1001773695

http://www.w3.org/2001/XMLSchema#string

P698

16865597

http://www.w3.org/2001/XMLSchema#string